Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

J&J And Boehringer Sign Diabetes Deals

by Michael McCoy
June 28, 2010 | A version of this story appeared in Volume 88, Issue 26

Johnson & Johnson’s Ortho-McNeil-Janssen Pharmaceuticals unit has signed diabetes drug development pacts with Diamyd Medical and Metabolex. Ortho will pay Diamyd $45 million up front for rights to develop the pharmaceutical protein rhGAD65, which is in Phase III trials as a treatment for newly diagnosed type 1 diabetes patients. Meanwhile, Ortho will pay Metabolex an undisclosed upfront payment as part of a development and license agreement involving compounds for the treatment of type 2 diabetes. Separately, Boehringer Ingelheim will pay Neurocrine Biosciences $10 million for rights to develop small molecules that activate GPR119, a G-protein-coupled receptor, as a way of treating type 2 diabetes.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.